This program will be of substantial interest to endocrinologists and fellows caring for individuals with, or at risk for developing, obesity and associated diseases. Additionally, this program may be of interest to primary care professionals and advance practice professionals who treat patients with obesity.

Upon completing this series, learners will be able to:

1. Identify new and emerging trends in obesity medicine and management;
2. Identify and review available and emerging therapeutic approaches to obesity management;
3. Review different approaches to weight loss/maintenance.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 12.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

The core faculty for Project ECHO: Approaches to Long-Term Weight Loss and Obesity Care are:

Amy E. Rothberg, MD, PhD - Program Chair
University of Michigan 

Jamy Ard, MD
Wake Forest School of Medicine 

Donna H. Ryan, MD
Pennington Biomedical Research Center

Jonathan Purnell, MD
Oregon Health and Science University

Beret A. Casey, MD - Peer Reviewer
Essentia Health

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following faculty reported relevant financial relationships: Amy E. Rothberg, MD, PhD - Self: Rhythm, Consultant/Advisory; Spouse: Merck, Data Safety Monitoring Board. Jonathan Purnell, MD - Self: Novo Nordisk, Advisor Board - Global Obesity Program. Jamy Ard, MD - Self: Novo Nordisk, UnitedHealth Group, Boehringer-Ingelheim, Nestle Healthcare Nutrition, Consultant; Epitomee Medical, Research Grant. Donna H. Ryan, MD - Self: Alyvent, Bausch Health, Boeringer Ingelheim, Epitomee, Janssen, Novo Nordisk, real appeal (United Health), ReDesign Health, and Sanofi - Consulting Fee. Self: Novo Nordisk, Bausch Health - Speakers Bureau. Self: Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health and Scientific Intake - Ownership Interest. Self: SELECT Steering Committee (Novo Nordisk) - Research.

Disclosure information for guest speakers is included in their individual recorded presentations.

The following peer reviewer reported no relevant financial relationships: Beret A. Casey, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an independent medical educational grant from Novo Nordisk Inc.